Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Context: Although type 2 diabetes (T2D) is a risk factor for liver fibrosis in nonalcoholic fatty liver disease (NAFLD), the specific contribution of insulin resistance (IR) relative to other factors is unknown. Objective: Assess the impact on liver fibrosis in NAFLD of adipose tissue (adipose tissue insulin resistance index [adipo-IR]) and liver (Homeostatic Model Assessment of Insulin Resistance [HOMA-IR]) IR in people with T2D and NAFLD. Design: Participants were screened by elastography in the outpatient clinics for hepatic steatosis and fibrosis, including routine metabolites, cytokeratin-18 (a marker of hepatocyte apoptosis/steatohepatitis), and HOMA-IR/adipo-IR. Setting: University ambulatory care practice. Participants: A total of 483 participants with T2D. Intervention: Screening for steatosis and fibrosis with elastography. Main outcome measures: Liver steatosis (controlled attenuation parameter), fibrosis (liver stiffness measurement), and measurements of IR (adipo-IR, HOMA-IR) and fibrosis (cytokeratin-18). Results: Clinically significant liver fibrosis (stage F ≥ 2 = liver stiffness measurement ≥8.0 kPa) was found in 11%, having more features of the metabolic syndrome, lower adiponectin, and higher aspartate aminotransferase (AST), alanine aminotransferase, liver fat, and cytokeratin-18 (P < 0.05-0.01). In multivariable analysis including just clinical variables (model 1), obesity (body mass index [BMI]) had the strongest association with fibrosis (odds ratio, 2.56; CI, 1.87-3.50; P < 0.01). When metabolic measurements and cytokeratin-18 were included (model 2), only BMI, AST, and liver fat remained significant. When fibrosis stage was adjusted for BMI, AST, and steatosis (model 3), only Adipo-IR remained strongly associated with fibrosis (OR, 1.51; CI, 1.05-2.16; P = 0.03), but not BMI, hepatic IR, or steatosis. Conclusions: These findings pinpoint to the central role of dysfunctional, insulin-resistant adipose tissue to advanced fibrosis in T2D, beyond simply BMI or steatosis. The clinical implication is that targeting adipose tissue should be the priority of treatment in NAFLD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the adipose tissue insulin resistance index (Adipo-IR) even predicts the severity of hepatic fi brosis. 222”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [222]
In the citing paper
“Individuals with metabolic dysfunction-associated steatotic liver/steatohepatitis (MASL/MASH) also exhibit adipose tissue IR (Adipo-IR), i.e. despite high insulin concentrations, lipolysis is not suppressed, especially during the fasting state[8], [9], [10].”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [10]
In the citing paper
“Adipo-IR is associated with a lipidomic profile enriched with saturated lipids,11 increased macrophage activity,9 and severity of hepatic fibrosis.10,12”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [10]
In the citing paper
“The combination of high FFA flux and high insulin promotes the uptake and re-esterification of FFAs into TAGs by peripheral tissues, including the liver,11,46 and has been associated with worse histology and increased fibrosis.9,10,47”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [10]
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationYounossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Eddowes, P. J., Sasso, M., Allison, M., Tsochatzis, E., Anstee, Q. M., Sheridan, D., Guha, I. N., Cobbold, J. F., Deeks, J. J., Paradis, V., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.042 · Cited by 1,410
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,198
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationCusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Self-citationThe complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Self-citationA Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593
Self-citationGastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
Self-citationFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Self-citationLomonaco, R., Godinez Leiva, E., Bril, F., Shrestha, S., Mansour, L., Budd, J., Portillo Romero, J., Schmidt, S., Chang, K.-L., Samraj, G., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1997 · Cited by 354
Self-citationKoehler, E. M., Plompen, E. P. C., Schouten, J. N. L., Hansen, B. E., Darwish Murad, S., Taimr, P., Leebeek, F. W. G., Hofman, A., Stricker, B. H., Castera, L., et al. (2016) · Hepatology · doi:10.1002/hep.27981 · Cited by 321
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Self-citationHarrison, S. A., Gawrieh, S., Roberts, K., Lisanti, C. J., Schwope, R. B., Cebe, K. M., Paradis, V., Bedossa, P., Aldridge Whitehead, J. M., Labourdette, A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.034 · Cited by 293
Bril, F., Barb, D., Portillo‐Sanchez, P., Biernacki, D., Lomonaco, R., Suman, A., Weber, M. H., Budd, J. T., Lupi, M. E., & Cusi, K. (2017) · Hepatology · doi:10.1002/hep.28985 · Cited by 288
Self-citationGastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology · doi:10.1002/hep.23116 · Cited by 285
Self-citationAmerican Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s004 · Cited by 285
Gurka, M. J., Lilly, C. L., Oliver, M. N., & DeBoer, M. D. (2014) · Metabolism · doi:10.1016/j.metabol.2013.10.006 · Cited by 262
Self-citationOrtiz-Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V. G., Hardies, J., & Cusi, K. (2012) · Diabetes Care · doi:10.2337/dc11-1849 · Cited by 253
Self-citationHow to Measure Adipose Tissue Insulin Sensitivity
Søndergaard, E., Espinosa De Ycaza, A. E., Morgan-Bathke, M., & Jensen, M. D. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00047 · Cited by 198
Ciardullo, S., Monti, T., & Perseghin, G. (2021) · Diabetes Care · doi:10.2337/dc20-1778 · Cited by 188
Barb, D., Repetto, E. M., Stokes, M. E., Shankar, S. S., & Cusi, K. (2021) · Obesity · doi:10.1002/oby.23263 · Cited by 146
Self-citationBouchi, R., Nakano, Y., Fukuda, T., Takeuchi, T., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0449 · Cited by 113
Gastaldelli, A., Sabatini, S., Carli, F., Gaggini, M., Bril, F., Belfort‐DeAguiar, R., Positano, V., Barb, D., Kadiyala, S., Harrison, S., et al. (2021) · Liver International · doi:10.1111/liv.15005 · Cited by 101
Self-citationNonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
Budd, J., & Cusi, K. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.01.007 · Cited by 60
Self-citationOhta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 56
Preparing for the NASH Epidemic: A Call to Action
Kanwal, F., Shubrook, J. H., Younossi, Z., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C., Pfotenhauer, K., Klein, S., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0020 · Cited by 45
Self-citationDeBoer, M. D., Lin, B., Filipp, S. L., Cusi, K. J., & Gurka, M. J. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.12.023 · Cited by 15
Self-citation25OCT22_Supplementary_Figures.Kalavalapalli_et.al.JCEM_2022.docx
Kalavalapalli, S., Leiva, E. G., Lomonaco, R., Gurka, M. J., & Cusi, K. J. (2022) · Figshare · doi:10.6084/m9.figshare.21396960 · Cited by 1
Self-citation
Cited by
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms
Steinberg, G. R., Valvano, C. M., De Nardo, W., & Watt, M. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.033 · Cited by 240
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Nogueira, J. P., & Cusi, K. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0013 · Cited by 110
Self-citation
Metadata
- Authors
- Kalavalapalli, S., Leiva, E. G., Lomonaco, R., Chi, X., Shrestha, S., Dillard, R., Budd, J., Romero, J. P., Li, C., Bril, F., Samraj, G., Pennington, J., Townsend, P., Orlando, F., Shetty, S., Mansour, L., Silva-Sombra, L. R., Bedossa, P., Malaty, J., Barb, D., Gurka, M. J., & Cusi, K.
- Affiliations
- University of Florida Health (US)
- Division of General Internal Medicine, University of Florida , Gainesville, FL 32606 , USA
- University of Florida (US)
- Publique-Hôpitaux de Paris, Beaujon Hospital, Pathology Department and University Paris-Diderot , 75116 Paris , France
- Corresponding author
- Cusi, Kenneth
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2022-11-16
- Volume
- 108
- Issue
- 5
- Pages
- 1192-1201
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W4309161291
- Cited by
- 64
- References
- 31
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 17 · 2023: 8
- FWCI
- 8.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Echosens
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- adipose tissue insulin resistance, liver fibrosis, type 2 diabetes, non-alcoholic fatty liver disease, HOMA-IR, hepatic steatosis, cytokeratin 18, liver stiffness measurement, controlled attenuation parameter, obesity, adiponectin, metabolic syndrome, hepatocyte apoptosis, elastography, fibrosis severity prediction, hepatic insulin resistance, aspartate aminotransferase
- MeSH terms
- Adipose Tissue, Diabetes Mellitus, Type 2, Fibrosis, Humans, Insulin, Insulin Resistance, Liver, Liver Cirrhosis, Keratin-18, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.